| Literature DB >> 33063732 |
Li-Qiong Yuan1, Qing Zeng1, Dan Wang2, Xiu-Yun Wen2, Yu Shi1, Fen Zhu2, Shang-Jie Chen2, Guo-Zhi Huang3.
Abstract
Individuals with amnestic mild cognitive impairment (aMCI) have a high risk of developing Alzheimer's disease. Although repetitive transcranial magnetic stimulation (rTMS) is considered a potentially effective treatment for cognitive impairment in patients with aMCI, the neuroimaging mechanisms are poorly understood. Therefore, we performed a double-blind randomized sham-controlled trial in which rTMS was applied to the left dorsolateral prefrontal cortex of aMCI patients recruited from a community near the Third Hospital Affiliated to Sun Yat-sen University, China. Twenty-four patients with aMCI were randomly assigned to receive true rTMS (treatment group, n = 12, 6 men and 6 women; age 65.08 ± 4.89 years) or sham stimulation (sham group, n = 12, 5 men and 7 women; age 64.67 ± 4.77 years). rTMS parameters included a stimulation frequency of 10 Hz, stimulation duration of 2 seconds, stimulation interval of 8 seconds, 20 repetitions at 80% of the motor threshold, and 400 pulses per session. rTMS/sham stimulation was performed five times per week over a period of 4 consecutive weeks. Our results showed that compared with baseline, Montreal Cognitive Assessment scores were significantly increased and the value of the amplitude of low-frequency fluctuation (ALFF) was significantly increased at the end of treatment and 1 month after treatment. Compared with the sham group, the ALFF values in the right inferior frontal gyrus, triangular part of the inferior frontal gyrus, right precuneus, left angular gyrus, and right supramarginal gyrus were significantly increased, and the ALFF values in the right superior frontal gyrus were significantly decreased in the treatment group. These findings suggest that high-frequency rTMS can effectively improve cognitive function in aMCI patients and alter spontaneous brain activity in cognitive-related brain areas. This study was approved by the Ethics Committee of Shenzhen Baoan Hospital of Southern Medical University, China (approval No. BYL20190901) on September 3, 2019, and registered in the Chinese Clinical Trials Registry (registration No. ChiCTR1900028180) on December 14, 2019.Entities:
Keywords: Alzheimer’s disease; clinical trial; cognitive function; cognitive impairment; functional magnetic resonance imaging; neurological function; repetitive transcranial magnetic stimulation
Year: 2021 PMID: 33063732 PMCID: PMC8067941 DOI: 10.4103/1673-5374.295345
Source DB: PubMed Journal: Neural Regen Res ISSN: 1673-5374 Impact factor: 5.135
The specific values of the clusters with significant differences in amnestic mild cognitive impairment patients after rTMS or sham stimulation
| Clusters | Brodmann area | Voxels | MNI coordinates (mm) | ||||
|---|---|---|---|---|---|---|---|
| Treatment group | Right middle frontal | 46 | 102 | 45 | 30 | 21 | 3.9699 |
| Sham group | Right middle frontal | 46 | 173 | 39 | 48 | 0 | –5.3776 |
| Right supramarginal | 40 | 121 | 66 | –39 | 33 | –8.8384 | |
| Left precuneus | 31 | 342 | 0 | –60 | 33 | –13.5093 | |
| Intergroup | Right inferior frontal gyrus, triangular part | 46 | 380 | 48 | 30 | 18 | 6.3389 |
| Right precuneus | 31 | 285 | 15 | –63 | 45 | 5.8361 | |
| Lift angular | 39 | 152 | –48 | –51 | 27 | 4.6104 | |
| Right supramarginal | 40 | 173 | 63 | –42 | 33 | 5.2888 | |
| Right superior frontal gyrus | 6 | 159 | 21 | 3 | 63 | –5.4426 | |
MNI: Montreal Neurological Institute; rTMS: repetitive transcranial magnetic stimulation. All clusters in Table 2 were P < 0.05.
Characteristics of amnestic mild cognitive impairment patients after repetitive transcranial magnetic stimulation or sham stimulation
| Characteristics | Treatment group | Sham group | |
|---|---|---|---|
| Sex (male/female, | 6/6 | 5/7 | 0.698 |
| Age (yr) | 65.08±4.89 | 64.67±4.77 | 0.835 |
| Education (yr) | 11.83±2.37 | 11.33±2.15 | 0.500 |
| Course of disease (yr) | 4.25±2.26 | 3.50±2.23 | 0.423 |
| Montreal Cognitive Assessment | 22.83±1.11 | 22.00±1.28 | 0.103 |
Data are expressed as the mean ± SD (n = 12), except sex. All data were analyzed via a two-sample t-test.
| group | Age (yr) | Education(yr) | Sex | Course of disease (yr) | Pre-MoCA | 1 day after | 1 mon after MoCA |
|---|---|---|---|---|---|---|---|
| 1 | 70 | 11 | 2 | 1 | 22 | 26 | 23 |
| 1 | 71 | 8 | 1 | 2 | 23 | 26 | 25 |
| 1 | 72 | 14 | 2 | 3 | 23 | 27 | 24 |
| 1 | 60 | 14 | 1 | 4 | 21 | 26 | 25 |
| 1 | 64 | 12 | 1 | 4 | 23 | 25 | 24 |
| 1 | 60 | 11 | 1 | 4 | 25 | 24 | 26 |
| 1 | 68 | 12 | 2 | 5 | 23 | 23 | 23 |
| 1 | 60 | 15 | 1 | 10 | 21 | 25 | 24 |
| 1 | 68 | 11 | 2 | 5 | 23 | 23 | 22 |
| 1 | 68 | 11 | 2 | 6 | 23 | 25 | 26 |
| 1 | 60 | 15 | 1 | 4 | 23 | 25 | 23 |
| 1 | 60 | 8 | 2 | 3 | 24 | 26 | 24 |
| 2 | 63 | 8 | 1 | 3 | 23 | 23 | 23 |
| 2 | 59 | 11 | 2 | 4 | 24 | 23 | 23 |
| 2 | 64 | 11 | 2 | 3 | 21 | 21 | 21 |
| 2 | 60 | 11 | 1 | 4 | 21 | 23 | 20 |
| 2 | 68 | 11 | 2 | 7 | 21 | 22 | 23 |
| 2 | 60 | 11 | 1 | 8 | 23 | 23 | 21 |
| 2 | 64 | 11 | 2 | 2 | 24 | 21 | 19 |
| 2 | 60 | 11 | 2 | 1 | 21 | 23 | 21 |
| 2 | 73 | 11 | 2 | 1 | 21 | 20 | 21 |
| 2 | 71 | 15 | 1 | 2 | 21 | 23 | 23 |
| 2 | 70 | 14 | 1 | 2 | 21 | 21 | 21 |
| 2 | 64 | 8 | 2 | 5 | 23 | 24 | 23 |
remark: group1=Treatment group, group2=Sham group;sex1=male, sex2=female